TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating reaffirmed by analysts at Noble Financial in a research note issued to investors on Thursday.

Several other equities research analysts have also issued reports on the company. Deutsche Bank set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research note on Tuesday, August 22nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a research note on Monday, August 21st. Oppenheimer set a $10.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research note on Thursday, August 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a research note on Monday, September 4th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. TherapeuticsMD presently has an average rating of “Buy” and a consensus price target of $14.50.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded down $0.10 during trading on Thursday, reaching $6.20. The company had a trading volume of 3,573,467 shares, compared to its average volume of 2,906,673. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The company had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same period in the prior year, the company earned ($0.13) earnings per share. The firm’s revenue was down 19.7% on a year-over-year basis. equities analysts anticipate that TherapeuticsMD will post -0.37 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of TXMD. Teachers Advisors LLC raised its holdings in shares of TherapeuticsMD by 1.4% in the first quarter. Teachers Advisors LLC now owns 639,602 shares of the company’s stock worth $4,605,000 after buying an additional 9,077 shares during the period. Vanguard Group Inc. raised its holdings in shares of TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock worth $70,574,000 after buying an additional 515,992 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in TherapeuticsMD by 10.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock worth $4,510,000 after purchasing an additional 60,229 shares during the period. State Street Corp increased its holdings in TherapeuticsMD by 6.9% during the 1st quarter. State Street Corp now owns 3,903,491 shares of the company’s stock worth $28,105,000 after purchasing an additional 253,237 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its holdings in TherapeuticsMD by 3.5% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 103,048 shares of the company’s stock worth $742,000 after purchasing an additional 3,472 shares during the period. Hedge funds and other institutional investors own 73.72% of the company’s stock.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/01/therapeuticsmd-txmd-rating-reiterated-by-noble-financial.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.